Biotechnology company Halozyme Therapeutics Inc (NASDAQ:HALO) said on Wednesday that it has successfully filed a Biologics License Application for a subcutaneous (SC) formulation of trastuzumab (Herceptin) under the US Food and Drug Administration's (FDA) approved breast cancer indications.
Herceptin is reportedly a registered trademark of Genentech and Herceptin's BLA has been submitted by Genentech, a member of the Roche Group.
For 2017, Roche reported sales of Herceptin of CHF2.7bn in the US. Sales of subcutaneous trastuzumab will be dependent on market adoption.
This is a co-formulation with Halozyme's proprietary recombinant human hyaluronidase enzyme (ENHANZE technology), which is approved and marketed under the Herceptin SC brand in many countries outside the US.
(EUR1= CHF1.16)
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval